Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the … (NCT05651997) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee
Switzerland80 participantsStarted 2026-12
Plain-language summary
The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.
Who can participate
Age range
15 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged between 15-50 years
* Symptomatic chondral and osteochondral defect, grade III and IV according to the ICRS classification, and size between 2.5 and 15 cm2
* Failure of a conservative treatment
* Patient in good general condition, documented by an ASA score ≤ 2 (American Society of Anesthesiologists)
* Patient considered compliant and able to participate in rehabilitation and pre- and post-operative follow-up
* Consent to participate in the study
Exclusion Criteria:
* All inflammatory and synovial pathologies
* Diffuse or mirror lesions
* An unfavorable biomechanical environment
* Obesity grade II or higher, with a BMI\>35 kg/m2
* Active smoking/ active drug dependency (hard drugs)
* Poor compliance
* The patient is already part of another clinical trial that may compromise the present study
* Vulnerable populations (except minors aged 15-18 years)
* Presence of open growth plate (15-18 years)
* Pregnancy or planned pregnancy during the study (MRI-related contra-indication)
* Proven allergy to penicillin and gentamicin (for MACT group) and porcine collagen (for both groups)
For final inclusion, an additional exclusion criteria will be assessed after randomization:
\- Positive to HIV, HBV, HCV, syphilis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Patellofemoral joint-related function and quality-of-life are assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS).
Timeframe: Change from baseline to 3, 6 12, 24, 36, 48 and 60 months post-implantation in the patellofemoral joint.